Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor

Neuroscience Letters

Volumn 341, Issue 3, 2003, Pages 233-236

  Maruyama, Wakako ^a   Weinstock, Marta ^b   Youdim, Moussa B H ^c   Nagai, Masayo ^a   Naoi, Makoto ^d  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b HEBREW UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Institute of Applied Biochemistry   (Japan)

Author keywords

Alzheimer's disease; Anti apoptotic activity; Cholinesterase inhibitor; Lewy Body disease; Mitochondrial membrane potential; Monoamine oxidase inhibitor; Parkinson's disease; Peroxynitrite; Propargylamines; Rasagiline; TV3326

Indexed keywords

CHOLINESTERASE INHIBITOR; LADOSTIGIL; MONOAMINE OXIDASE INHIBITOR; NOOTROPIC AGENT; PEROXYNITRITE; RASAGILINE; UNCLASSIFIED DRUG; [(N PROPARGYL)AMINOINDAN 5 YL]ETHYLMETHYLCARBAMATE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CELL STRAIN; COGNITIVE DEFECT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG SCREENING; ENANTIOMER; HUMAN; HUMAN CELL; NEUROPROTECTION; PHARMACOPHORE; PRIORITY JOURNAL;

EID: 0345237921     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00211-8     Document Type: Article

References (20)

1. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M.B.H., Tsujimoto Y., Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82:2002;913-923.
2. Campbell S., Stephens S., Ballard C. Dementia with Lewy bodies: clinical features and treatment. Drugs Aging. 18:2001;397-407.
3. Carrillo M.C., Minami C., Kitani K., Maruyama W., Ohashi K., Yamamoto T., Naoi M., Kanai S., Youdim M.B.H. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 67:2000;577-585.
4. Finberg J.P., Takeshima T., Johnston J.M., Commissiong J.W. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. NeuroReport. 9:1998;703-707.
5. Group P.S. A controlled trial of rasagiline in early Parkinson disease. Arch. Neurol. 59:2002;937-1943.
6. Huang W., Chen Y., Shohami E., Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur. J. Pharmacol. 366:1999;127-135.
7. Maruyama W., Akao Y., Youdim M.B.H., Boulton A.A., Davis B.A., Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78:2001;727-735.
8. Maruyama W., Akao Y., Youdim M.B.H., Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N- propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. (Suppl.). 2000;171-186.
9. Maruyama W., Boulton A.A., Davis B.A., Dostert P., Naoi M. Enantio-specific induction of apoptosis by an endogenous neurotoxin N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J. Neural Transm. 108:2001;11-24.
10. Maruyama W., Takahashi T., Naoi M. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J. Neurochem. 70:1998;2510-2515.
11. Maruyama W., Youdim M.B.H., Naoi M. Antiapoptotic properties of rasagiline N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. N.Y. Acad. Sci. 939:2001;320-329.
12. Naoi M., Maruyama W., Takahashi T., Akao Y., Nakagawa Y. Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. J. Neural Transm. (Suppl.). 58:2000;111-121.
13. Pastorino J.G., Simbula G., Yamamoto K., Glascott P.A. Jr, Rothman R.J., Farber J.L. The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition. J. Biol. Chem. 271:1996;29792-29798.
14. Sagi Y., Weinreb O., Weinstock M., Youdim M.B.H. Neuroprotective and neurorescue properties of rasagiline and TV3326 in MPTP model of Parkinson's disease. Neural Plasticity. 8:2001;197-198.
15. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
16. Weinstock M., Bejar C., Wang R.H., Poltyrev T., Gross A., Finberg J., Youdim M.B.H. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. (Suppl.). 60:2000;S157-S170.
17. Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M.B.H., Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. N.Y. Acad. Sci. 939:2001;148-161.
18. Yogev-Falach M., Amit T., Bar-Am O., Sagi Y., Weinstock M., Youdim M.B.H. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 16:2002;1674-1676.
19. Youdim M.B.H., Gross A., Finberg J.P.M. Rasagiline [N-Propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132:2001;500-506.
20. Youdim M.B.H., Wadia A., Tatton N.A., Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N. Y. Acad. Sci. 939:2001;450-458.